SHINVA MEDICAL INSTRUMENT CO.,LTD. Shinva Medical Instrument Co.,Ltd. Stock
Equities
600587
CNE000001CN3
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.36 CNY | +6.16% |
|
+4.04% | -17.18% |
| Sales 2024 * | 10.95B 1.51B | Sales 2025 * | 12.59B 1.74B | Capitalization | 9.97B 1.38B |
|---|---|---|---|---|---|
| Net income 2024 * | 817M 113M | Net income 2025 * | 1.04B 143M | EV / Sales 2024 * | 0.91 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.79 x |
| P/E ratio 2024 * |
12.2
x | P/E ratio 2025 * |
9.59
x | Employees | 8,209 |
| Yield 2024 * |
1.26% | Yield 2025 * |
1.54% | Free-Float | 65.99% |
More Fundamentals
* Assessed data
More news
| 1 day | +6.16% | ||
| 1 week | +4.04% | ||
| Current month | -6.56% | ||
| 1 month | -8.40% | ||
| 3 months | -1.57% | ||
| 6 months | -2.47% | ||
| Current year | -17.18% |
1 week
20.02
21.55
1 month
20.0223.50
Current year
17.1225.88
1 year
17.1236.95
3 years
15.0036.95
5 years
11.6736.95
10 years
10.7358.63
| Managers | Title | Age | Since |
|---|---|---|---|
Bao Xian Gong
CEO | Chief Executive Officer | 48 | 22-02-22 |
Juan Juan Zhou
DFI | Director of Finance/CFO | 44 | 21-08-12 |
Yu Quan Wang
CHM | Chairman | 56 | 10-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yue Yong Wang
BRD | Director/Board Member | 59 | 21-01-26 |
Ai Ling Pan
BRD | Director/Board Member | 59 | 20-05-14 |
Li Yong Jiang
BRD | Director/Board Member | 48 | 21-01-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +1.63% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-22 | 21.36 | +6.16% | 11,383,530 |
| 24-04-19 | 20.12 | -1.23% | 5,165,163 |
| 24-04-18 | 20.37 | +0.20% | 8,090,012 |
| 24-04-17 | 20.33 | +1.30% | 9,301,100 |
| 24-04-16 | 20.07 | -2.24% | 6,717,924 |
End-of-day quote Shanghai S.E., April 21, 2024
More quotes
Shinva Medical Instrument Co Ltd is a China-based company principally engaged in the production and sales of medical devices and pharmaceutical equipment. The Company primarily operates its businesses through four segments. The Medical Device Products segment mainly provides infection control equipment and consumables, radiotherapy and imaging, in vitro diagnostic reagents and instruments, surgical instruments and orthopedics and other products. The Pharmaceutical Equipment Product segment mainly includes injections, biopharmaceuticals, solid preparations, traditional Chinese medicine preparations and other businesses. The Medical Services segment mainly develops specialized hospitals for hemodialysis. The Medical Commercial Products segment is mainly engaged in commercial logistics business.
Calendar
2024-04-29
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
21.36
CNY
Average target price
31.53
CNY
Spread / Average Target
+47.61%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -17.18% | 1.38B | |
| -2.73% | 186B | |
| -2.20% | 107B | |
| -4.08% | 67.57B | |
| +5.99% | 50.7B | |
| +15.32% | 47.2B | |
| -0.45% | 39.72B | |
| +6.60% | 27.48B | |
| -1.11% | 25.65B | |
| -0.76% | 24.82B |
- Stock Market
- Equities
- 600587 Stock
